CXCL10和MMP-13在妊娠滋养细胞疾病滋养细胞中的表达及其临床意义

目的检测妊娠滋养细胞疾病滋养细胞中CXCL10和MMP-13表达情况,探讨其在滋养细胞疾病浸润和转移中的作用。方法采用免疫组织化学Powervision法检测40例早孕绒毛,30例葡萄胎,18例葡萄胎恶变(随访发生恶变),35例滋养细胞肿瘤(28例绒癌,7例胎盘部位滋养细胞肿瘤)中CXCL10和MMP-13的表达。结果CXCL10和MMP-13在滋养细胞肿瘤中表达阳性率和免疫反应性强度最高;在葡萄胎恶变组中表达阳性率和免疫反应性强度较高,但是低于在滋养细胞肿瘤中的表达阳性率和免疫反应性强度;在葡萄胎组和早孕绒毛组中表达阳性率和免疫强度较低。CXCL10和MMP-13在滋养细胞肿瘤中的表达,年龄<40岁组中表达低于年龄>40岁组;在临床分期分组(Ⅰ、Ⅱ)中表达低于临床分期分组(Ⅲ、Ⅳ);在FIGO预后评分分组低危组中表达低于高危组。结论CXCL10和MMP-13在早孕绒毛组织中低表达,而在滋养细胞肿瘤中高表达,提示其可能参与滋养细胞疾病的浸润和转移过程,因此联合检测CXCL10和MMP-13的表达可能对葡萄胎恶变的早期诊断以及对滋养细胞肿瘤的预后评估提供依据。     

miR-21在大鼠心肌细胞缺血再灌注损伤中的作用机制研究

摘要 目的：探讨微小RNA-21（miR-21）在大鼠心肌细胞缺血再灌注损伤中的作用机制。方法：选取50只SPF级Wistar大鼠并随机分为5组（n=10）,分别为对照组、模型组、模型+阴性对照组、模型+ miR-21组和模型+ miR-21抑制物组。通过结扎大鼠左冠前降支进行建模。建模成功后采用高频彩色超声诊断仪检查各组大鼠的心脏功能指标：心脏射血分数（EF）、左心室收缩期峰值压力（LVSP）、左室舒张末压（LVEDP）和缩短分数（FS）。检测各组大鼠心肌梗死面积和心肌细胞凋亡率。采用酶联免疫吸附试验（ELISA）测定各组心肌组织中肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）和白细胞介素-10（IL-10）的含量。采用反转录聚合酶链式反应（RT-PCR）检测心肌组织中miR-21的表达水平。蛋白免疫印迹试验（Western Blot）检测各组大鼠心肌凋亡蛋白和TLR4/NF-κB表达水平。结果：模型组大鼠出现心肌梗死,提示建模成功,建模后大鼠心肌组织中miR-21的表达水平显著下降,提示miR-21可能具有保护心肌细胞的作用。建模成功后,EF、LVSP和FS下降,LVEDP升高,心肌细胞凋亡率显著升高,TNF-α和IL-6表达水平显著升高,IL-10显著下降,Bcl-2/Bax表达下降,Caspase-3表达升高,大鼠心肌细胞TLR4和NF-κB蛋白磷酸化表达水平升高,而模型+ miR-21组上述指标均得到改善。结论：大鼠心肌细胞缺血再灌注损伤导致miR-21表达降低,而过表达miR-21能有效抑制TLR4/NF-κB信号通路,降低大鼠心肌凋亡水平和炎症因子的释放,从而发挥保护心肌细胞的作用。     

CD4^＋T细胞在大鼠心肌缺血再灌注损伤中的作用

目的通过大鼠心肌缺血再灌注损伤的动物模型,分析CD4^＋T细胞在心肌组织损伤中的作用。方法结扎大鼠冠状动脉左前降支45min,随后恢复再灌的方法,制作缺血再灌损伤的动物模型,随机分为再灌注0、2、6、9、12h组及相应的对照组。II导联心电图及TTC确定模型,组织病理学观察心肌细胞的损伤情况,免疫荧光染色计数浸润的炎性细胞,半定量PCR进一步验证各型T细胞的表达。结果心肌的梗死面积与心肌缺血再灌时间成正相关,至观察结束未出现峰值;组织中浸润的中型粒细胞和T细胞分别在2h和12h有峰值出现,但CD4^＋T/CD3^＋T的比率几乎保持不变;观察所见CD4^＋T细胞是组织中存在最多的T细胞。结论大鼠缺血再灌注损伤中,心肌组织中浸润的CD4^＋T细胞作为主要的效应细胞,参与了持续稳定的心肌损伤过程。     

体外心肌细胞缺血再灌注损伤模型的建立

目的建立体外心肌细胞缺血再灌注(I/R)模型,为研究各种心血管疾病及药物治疗提供基础.方法体外培养新生SD乳鼠心肌细胞,实验分正常组和缺血再灌注组.倒置显微镜及透射电子显微镜下观察心肌细胞缺血再灌注前后的形态变化,MTT、流式细胞术检测细胞凋亡情况,免疫组化和Western Blot检测Bcl-2/Bax基因表达.结果 I/R前后心肌细胞形态发生明显变化.与正常组相比,I/R组心肌细胞凋亡率明显增加,细胞活性降低.免疫组化和Western Blot检测结果均出现I/R后Bcl-2蛋白表达下调,Bax蛋白表达上调,Bcl-2/Bax显著减小的现象.结论体外培养的心肌细胞I/R损伤各项指标检测与动物体内实验结果相吻合,体外心肌细胞缺血再灌注模型建立成功.     

趋化因子CXCL12及其受体CXCR4在胶质瘤中的研究进展

CXCL12是趋化因子家族成员之一,是能够特异性结合其受体CXCR4发挥趋化性作用的细胞因子。最初,CXCL12及CXCR4被发现于炎症细胞,参与机体炎症、免疫等病理反应。接下来的几年中发现,它在机体发育、成熟过程中也有重要作用。如今,大量研究表明它与肿瘤的生长、侵袭及转移密切相关。据报道,在乳腺癌、肺癌、卵巢癌等二十余种肿瘤组织中发现CXCL12及CXCR4的表达,其中也包括中枢系统肿瘤-胶质瘤。CXCL12/CXCR4参与胶质瘤生长过程的多个步骤,包括肿瘤增殖、侵袭、转移等。有实验指出,转移灶的CXCR4表达水平较原发灶高,CXCR4有可能成为抑制胶质瘤生长、转移的重要靶目标。     

趋化因子CXCL12 及其受体CXCR4 在胶质瘤中的研究进展

CXCL12是趋化因子家族成员之一,是能够特异性结合其受体CXCR4发挥趋化性作用的细胞因子。最初,CXCL12及CXCR4被发现于炎症细胞,参与机体炎症、免疫等病理反应。接下来的几年中发现,它在机体发育、成熟过程中也有重要作用。如今,大量研究表明它与肿瘤的生长、侵袭及转移密切相关。据报道,在乳腺癌、肺癌、卵巢癌等二十余种肿瘤组织中发现CXCL12及CXCR4的表达,其中也包括中枢系统肿瘤-胶质瘤。CXCL12/CXCR4参与胶质瘤生长过程的多个步骤,包括肿瘤增殖、侵袭、转移等。有实验指出,转移灶的CXCR4表达水平较原发灶高,CXCR4有可能成为抑制胶质瘤生长、转移的重要靶目标。     

TLR7在1型糖尿病大鼠肾缺血再灌注损伤中的作用研究

目的:探讨Toll样受体7(TLR7)介导的My D88/NF-κB信号通路在1型糖尿病大鼠肾缺血再灌注损伤中的作用。方法:雄性SD大鼠随机分为3组(n=6),糖尿病假手术组(DS),糖尿病缺血再灌注组(DIR),糖尿病缺血再灌注+氯喹预处理组(DIR+CQ)。采用腹腔注射链尿佐菌素65 mg/kg建立糖尿病模型,TLR7抑制剂氯喹预处理于糖尿病模型成功后第3周0.5%氯喹40 mg/kg进行腹腔注射,连续给药7天。于第四周采用双侧肾蒂夹闭25 min,再灌注48 h建立肾缺血再灌注损伤模型。取大鼠肾脏HE染色观察大鼠病理学结果,血标本测定血尿素氮(BUN)和血肌酐(Scr)水平,ELISA法检测白细胞介素6(IL-6)和肿瘤坏死因子-α(TNF-α),TUNEL法检测细胞凋亡,Western blot检测TLR7,My D88和NF-κB蛋白表达。结果:与DS组相比,DIR组肾小管肿胀,间质水肿,刷状缘丢失,空泡变性坏死,Paller评分升高(P0.01)。与DIR组相比,氯喹预处理可以改善肾损伤(P=0.017);与DS组相比,DIR组BUN,Scr,IL-6,TNF-α,细胞调亡指数(Apoptosis%),TLR7,My D88,NF-κB增高(P0.05);与DIR组相比,DIR+CQ组BUN,Scr,IL-6,TNF-α,Apoptosis%,TLR7,My D88,NF-κB降低(P0.05)。结论:TLR7介导的My D88/NF-κB信号通路参与糖尿病肾缺血再灌注损伤,氯喹通过抑制TLR7表达,阻断My D88/NF-κB信号通路,降低炎症反应,从而减轻1型糖尿病大鼠肾缺血再灌注损伤。     

EPO对缺血/再灌注损伤大鼠心肌细胞Mfn2蛋白表达及心肌细胞凋亡的影响

目的观察重组人促红细胞生成素（recombinant human erythropoietin,rhEPO）对缺血/再灌注损伤大鼠心肌细胞Mitofusin2（Mfn2）蛋白表达的影响及其抗心肌细胞凋亡的作用。方法选取成年SD大鼠35只,随机分为正常组（Normal）,假手术组（Sham）,缺血再灌注组（I/R）,缺血再灌注EPO治疗组（I/R＋EPO）。各组分别于再灌注3h和24h后,剪取心脏缺血/再灌注损伤区域,用脱氧核苷酸末端转移酶介导的缺口末端标记法（TUNEL）检测心肌细胞凋亡,免疫组化法检测Mfn2蛋白的表达。结果再灌注3h和24h后,与正常组和假手术组相比,I/R组Mfn2蛋白的表达和心肌细胞凋亡均显著增加;与I/R组相比,I/R＋EPO组Mfn2蛋白的表达和心肌细胞凋亡均显著降低。结论EPO可以下调缺血再灌注损伤后心肌细胞Mfn2蛋白的表达,抑制心肌细胞的凋亡。     

缺血预处理减轻在体家兔心肌细胞凋亡

对麻醉家兔心肌缺血－再灌注（ｉｓｃｈｅｍｉａ－ｒｅｐｅｒｆｕｓｉｏｎ,ＩＲ）模型上,观察ＩＲ和缺血预处理（ｉｓｃｈｅｍｉｃ ｐｒｅｃｏｎｄｉｔｉｏｎｉｇｎ,ＩＰ）对血流动力学、心外膜电图、心肌梗塞范围、心肌细胞调亡和调亡相关调控基因蛋白（Ｆａｓ、Ｂｃｌ－２、Ｂａｘ等）的影响。所得结果如下：⑴在ＩＲ过程中,动脉血压、心率和心肌耗氧量进行性降低;心外膜电图ＳＴ段在缺血期明显抬高（Ｐ＜０．００１）,再灌     

诱导血红素加氧酶-1表达在器官移植中的保护作用

器官移植术中及术后移植器官的缺血再灌注损伤（ischemia-repeffusion injury,IRI）和免疫排斥反应一直困扰着外科医生.血红素加氧酶-1（heme oxygenase-1,HO-1）是血红素代谢过程中的限速酶,广泛分布于哺乳动物的各种组织细胞中.血红素在它的催化下降解代谢为一氧化碳（CO）、胆绿素和游离铁离子.HO-1在氧化应激、炎性反应、低氧和缺血等状态下均能高度表达.HO-1及其催化血红素代谢产物主要通过抗炎性反应、抗氧化反应、调节同种异体反应性T细胞的活性及增殖、抗内皮细胞凋亡、抑制内皮细胞活化等作用机制,对移植器官起到抗IRI和抗免疫排斥作用,从而增加移植器官成活率及延长其存活时间.     

Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12

Chemokines are important mediators of chemotaxis, cell adherence, and proliferation and exert specific functions in bone remodeling. Despite the potential intriguing role of chemokines in the regulation of osteoclast (OC) functions, little is known about the expression of chemokines and their receptors in human OCs at different stages of differentiation. Therefore, we analyzed the expression of CXC chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5) and ligands (CXCL8, CXCL10, CXCL12 and CXCL13) both at molecular and protein levels, in human OCs grown on plastic or calcium phosphate-coated slides at different stages of differentiation. Real-time PCR showed that CXCR1, CXCR2, CXCR3, CXCR4, CXCR5 and CXCL8 were expressed in undifferentiated cells and significantly decreased during OC differentiation. By contrast, CXCL10 and CXCL12 were strongly upregulated from day 0 to day 8 in cells grown on calcium phosphate-coated slides. Immunocytochemistry showed that OCs grown on plastic expressed CXCR3, CXCR4, CXCR5, CXCL8 and CXCL12, while they were negative for CXCR1, CXCR2 and CXCL10. Interestingly, both at molecular and protein levels CXCL10 and CXCL12 significantly increased only when cells were differentiated on calcium phosphate-coated slides. These data suggest that the selection of a substrate that better mimics the tridimensional structure of bone tissue, thus favoring OC maturation and differentiation, may be necessary when studying osteoclastogenesis in vitro.     

CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications

C–X–C motif chemokine 10 (CXCL10) also known as interferon γ-induced protein 10 kDa (IP-10) or small-inducible cytokine B10 is a cytokine belonging to the CXC chemokine family. CXCL10 binds CXCR3 receptor to induce chemotaxis, apoptosis, cell growth and angiostasis. Alterations in CXCL10 expression levels have been associated with inflammatory diseases including infectious diseases, immune dysfunction and tumor development. CXCL10 is also recognized as a biomarker that predicts severity of various diseases. A review of the emerging role of CXCL10 in pathogenesis of infectious diseases revealed diverse roles of CXCL10 in disease initiation and progression. The potential utilization of CXCL10 as a therapeutic target for infectious diseases is discussed.     

CXCR3, CXCL10 and type 1 diabetes

Type 1 diabetes (T1D) is due to antigen-specific assaults on the insulin producing pancreatic β-cells by diabetogenic T-helper (Th)1 cells. (C-X-C motif) ligand (CXCL)10, an interferon-γ inducible Th1 chemokine, and its receptor, (C-X-C motif) receptor (CXCR)3, have an important role in different autoimmune diseases. High circulating CXCL10 levels were detected in new onset T1D patients, in association with a Th1 autoimmune response. Furthermore β-cells produce CXCL10, under the influence of Th1 cytokines, that suppresses their proliferation. Viral β-cells infections induce cytokines and CXCL10 expression, inducing insulin-producing cell failure in T1D. CXCL10/CXCR3 system plays a critical role in the autoimmune process and in β-cells destruction in T1D. Blocking CXCL10 in new onset diabetes seems a possible approach for T1D treatment.     

CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways

Abnormal expression of CXC motif chemokine ligand 16 (CXCL16) has been demonstrated to be associated with tumor progression and metastasis, served as a prognostic factor in many cancers, with higher relative expression behaving as a marker of tumor progression. However, its role and mechanisms underlying progression and metastasis of gastric cancer (GC) are yet to be elucidated. In our investigation, public datasets and human GC tissue samples were used to determine the CXCL16 expression levels. Our results revealed that CXCL16 was upregulated in GC. The high expression CXCL16 in GC was significantly associated with histologic poor differentiation and pTNM staging. And high CXCL16 was positively correlated with the poor survival of GC patients. Gain-and loss-of-function experiments were employed to investigate the biological role of CXCL16 in proliferation and migration both in vitro and in vivo. Mechanically, Gene set enrichment analysis (GSEA) revealed that the epithelial‑mesenchymal transition (EMT), Akt and MAPK signal pathway related genes were significantly enriched in the high CXCL16 group, which was confirmed by western blot. Moreover, overexpression CXCL16 promoted the disintegrin and metalloproteases (ADAM10) and the CXC motif chemokine receptor 6 (CXCR6) expression, which mediated the CXCL16/CXCR6 positive feedback loop in GC, with activating Akt and MAPK signaling pathways. Knocking down ADAM10 would interrupted the CXCL16/CXCR6 axis in the carcinogenesis and progression of GC. In conclusion, our findings offered insights into that CXCL16 promoted GC tumorigenesis by enhancing ADAM10-dependent CXCL16/CXCR6 axis activation.     

阻断趋化因子CXCL10对脑缺血再灌注损伤及神经炎症的影响

目的:探讨趋化因子CXCL10在脑缺血再灌注损伤中对神经炎症的影响。方法:(1)线栓法建立脑缺血再灌注损伤大鼠模型,TTC染色检测梗死面积,Western blot检测CXCL10的表达;(2)建立小鼠神经瘤母细胞N2a氧糖剥夺/复氧(oxygen-glucose deprivation/reoxygenation,OGD/R)模型,通过CXCR3拮抗剂-NBI 74330阻断趋化因子CXCL10表达,Western blot检测CXCL10和CXCR3蛋白的表达;Real-time PCR检测CXCL10、CXCR3以及神经炎症因子TNF-α、IL-1β、IL-2 m RNA的表达。结果:(1)脑缺血再灌注(cerebral ischemia reperfusion injury,CIRI)模型大鼠脑梗死侧CXCR10的表达量显著高于其对侧和假手术组(P<0.05);(2)阻断CXCL10使得小鼠神经瘤母细胞N2a中CXCL10、CXCR3以及炎症因子TNF-α、IL-1β、IL-2的表达量均显著降低(P<0.05);(3)阻断CXCL10使得小鼠神经瘤母细胞细胞凋亡率降低(P<0.05)。结论:抑制CXCL10降低了氧糖剥夺模型细胞炎症因子的表达,表明阻断CXCL10可能通过减轻神经炎症在脑缺血再灌注损伤中发挥保护作用。     

Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation

We have already demonstrated that inactivated, replication-defective Sendai virus particles (HVJ-E) have a powerful antitumor effect by both the generation of tumor-specific cytotoxic T cells and inhibition of regulatory T cell activity. Here, we report that HVJ-E also has an antitumor effect through non-T cell immunity. Microarray analysis revealed that direct injection of HVJ-E induced the expression of CXCL10 in established Renca tumors. CXCL10 was secreted by dendritic cells in the tumors after HVJ-E injection. Quantitative real-time RT-PCR and immunohistochemistry revealed that CXCR3+ cells (predominantly NK cells) infiltrated the HVJ-E-injected tumors. Moreover, HVJ-E injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells. In an in vivo experiment, approximately 50% of tumors were eradicated by HVJ-E injection, and this activity of HVJ-E against Renca tumors was largely abolished by NK cell depletion using anti-asialo GM1 antibody. Since HVJ-E injection induced systemic antitumor immunity by enhancing or correcting the chemokine-chemokine receptor axis, it might be a potential new therapy for cancer.     

CD4+ T cell migration into the cornea is reduced in CXCL9 deficient but not CXCL10 deficient mice following herpes simplex virus type 1 infection

The role of CXCL9 and CXCL10 in the ocular immune response to herpes simplex virus type 1 (HSV-1) infection was investigated using mice deficient in either CXCL9 or CXCL10. CXCL10 but not CXCL9 deficient mice showed an increase in sensitivity to ocular virus infection as measured by an elevation in virus titer recovered in the tear film and corneal tissue. The increase in virus was associated with an increase in the expression of the chemokine CCL2 but no significant change in the infiltration of CD4(+) T cells or NK cells into the corneal stroma. In contrast, a significant reduction in CD4(+) T cell infiltration into the cornea was found in CXCL9 deficient mice following HSV-1 infection consistent with the absence of CXCL9 expression and reduction in expression of other chemokines including CCL3, CCL5, CXCL1, and CXCL10. Collectively, the results suggest a non-redundant role for CXCL9 and CXCL10 in response to ocular HSV-1 infection in terms of controlling virus replication and recruitment of CD4(+) T cells into the cornea.     

Skeletal muscle cell contraction reduces a novel myokine,chemokine (C-X-C motif) ligand 10 (CXCL10): potential roles in exercise-regulated angiogenesis

Accumulating evidence indicates that skeletal muscle secrets proteins referred to as myokines and that exercise contributes to their regulation. In this study, we propose that chemokine (C-X-C motif) ligand 10 (CXCL10) functions as a novel myokine. Initially, we stimulated differentiated C2C12 myotubes with or without electrical pulse stimulation (EPS) to identify novel myokines. Cytokine array analysis revealed that CXCL10 secretion was significantly reduced by EPS, which was further confirmed by enzyme-linked immunosorbent assay and quantitative polymerase chain reaction analysis. Treadmill experiments in mice identified significant reduction of Cxcl10 gene expression in the soleus muscle. Additionally, contraction-dependent p38 MAPK activation appeared to be involved in this reduction. Furthermore, C2C12 conditioned medium obtained after applying EPS could induce survival of MSS31, a vascular endothelial cell model, which was partially attenuated by the addition of recombinant CXCL10. Overall, our findings suggest CXCL10 as a novel exercise-reducible myokine, to control endothelial cell viability.